{"id":58720,"date":"2026-03-04T13:03:00","date_gmt":"2026-03-04T05:03:00","guid":{"rendered":"https:\/\/flcube.com\/?p=58720"},"modified":"2026-03-04T13:03:01","modified_gmt":"2026-03-04T05:03:01","slug":"asieris-pharmas-cevira-wins-nmpa-approval-worlds-first-non-surgical-photodynamic-therapy-for-cervical-lesions","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58720","title":{"rendered":"Asieris Pharma&#8217;s Cevira Wins NMPA Approval \u2013 World&#8217;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions"},"content":{"rendered":"\n<p><strong>Jiangsu Asieris Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688176:SHA\">SHA:\u202f688176<\/a>)<\/strong>, a <strong>urogenital cancer specialist<\/strong>, announced <strong>marketing approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>Cevira<\/strong>, a <strong>photodynamic drug\u2011device combination product<\/strong>. The <strong>world&#8217;s first non\u2011surgical, non\u2011invasive therapy<\/strong> for <strong>cervical intraepithelial neoplasia grade 2 (CIN2)<\/strong> represents a <strong>paradigm shift<\/strong> from <strong>surgical excision<\/strong> to <strong>topical, organ\u2011preserving treatment<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Cevira<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Photodynamic drug\u2011device combination product<\/td><\/tr><tr><td><strong>Components<\/strong><\/td><td>Hexaminolevulinate hydrochloride ointment + disposable cervical photodynamic therapy lamp<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA marketing approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cervical intraepithelial neoplasia grade 2 (CIN2)<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td><strong>World&#8217;s first<\/strong> non\u2011surgical, non\u2011invasive CIN2 therapy<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Topical ointment + intravaginal cold light source<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-clinical-evidence-global-multi-center-study\">Phase III Clinical Evidence \u2013 Global Multi\u2011Center Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Cevira Treatment Group<\/th><th>Placebo Group<\/th><th>Treatment Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>Response Rate (CIN2)<\/strong><\/td><td><strong>49.6%<\/strong><\/td><td>22.6%<\/td><td><strong>+27\u202fpercentage points<\/strong><\/td><\/tr><tr><td><strong>Histopathological Regression (6\u202fmonths)<\/strong><\/td><td><strong>57.5%<\/strong> regressed to normal\/LSIL<\/td><td>30.6%<\/td><td><strong>+26.9\u202fpercentage points<\/strong><\/td><\/tr><tr><td><strong>HPV Clearance (12\u202fmonths)<\/strong><\/td><td><strong>~\u202f60%<\/strong> baseline HPV cleared<\/td><td>\u2014<\/td><td>Significant viral elimination trend<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Paradigm Disruption:<\/strong> Cevira <strong>eliminates need for surgical excision<\/strong> (LEEP, cone biopsy) in CIN2 patients\u2014<strong>preserving cervical anatomy<\/strong>, <strong>reducing pregnancy complications<\/strong>, and <strong>eliminating surgical risks<\/strong> (bleeding, infection, cervical stenosis).<\/li>\n\n\n\n<li><strong>Global First\u2011in\u2011Class:<\/strong> As the <strong>world&#8217;s first approved non\u2011surgical CIN2 therapy<\/strong>, Cevira establishes <strong>Asieris as a pioneer<\/strong> in <strong>photodynamic gynecologic oncology<\/strong>, with <strong>licensing potential<\/strong> for <strong>US, EU, and emerging markets<\/strong>.<\/li>\n\n\n\n<li><strong>HPV Clearage Synergy:<\/strong> The <strong>~\u202f60% HPV clearance rate<\/strong> suggests <strong>dual therapeutic benefit<\/strong>\u2014<strong>lesion regression + viral elimination<\/strong>\u2014potentially <strong>reducing cervical cancer risk<\/strong> beyond surgical excision, which does not address underlying HPV infection.<\/li>\n\n\n\n<li><strong>Device\u2011Drug Integration:<\/strong> The <strong>proprietary cold light source + photosensitizer ointment<\/strong> creates <strong>competitive moats<\/strong> through <strong>IP protection<\/strong> and <strong>manufacturing complexity<\/strong>, supporting <strong>premium pricing<\/strong> and <strong>market exclusivity<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>CIN2 Prevalence<\/strong><\/td><td>~\u202f1\u20112% of screened women globally; ~\u202f3\u20115\u202fmillion annual cases in China; current standard is surgical excision with significant overtreatment<\/td><\/tr><tr><td><strong>Fertility Preservation<\/strong><\/td><td>Surgical excision increases preterm birth risk; Cevira&#8217;s non\u2011invasive approach addresses unmet need in women of childbearing age<\/td><\/tr><tr><td><strong>HPV Vaccine Complement<\/strong><\/td><td>Cevira treats existing lesions in vaccinated\/unvaccinated populations; potential for combination screening\u2011treatment programs<\/td><\/tr><tr><td><strong>Asieris Pipeline Synergy<\/strong><\/td><td>Cevira complements Asieris&#8217;s <strong>urogenital oncology portfolio<\/strong> (APL\u20111202 for bladder cancer); establishes platform for photodynamic expansion into other HPV\u2011related diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, reimbursement negotiations, and global partnership potential for Cevira. Actual results may differ due to risks including physician adoption curves, competitive loop electrosurgical excision procedure (LEEP) entrenchement, and long\u2011term recurrence data monitoring.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58722,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,22],"tags":[316,15,1127],"class_list":["post-58720","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-medical-device","tag-asieris-pharmaceuticals","tag-product-approvals","tag-sha-688176"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Asieris Pharma&#039;s Cevira Wins NMPA Approval \u2013 World&#039;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China&#039;s National Medical Products Administration (NMPA) for Cevira, a photodynamic drug\u2011device combination product. The world&#039;s first non\u2011surgical, non\u2011invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ\u2011preserving treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58720\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asieris Pharma&#039;s Cevira Wins NMPA Approval \u2013 World&#039;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China&#039;s National Medical Products Administration (NMPA) for Cevira, a photodynamic drug\u2011device combination product. The world&#039;s first non\u2011surgical, non\u2011invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ\u2011preserving treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58720\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T05:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T05:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Asieris Pharma&#8217;s Cevira Wins NMPA Approval \u2013 World&#8217;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions\",\"datePublished\":\"2026-03-04T05:03:00+00:00\",\"dateModified\":\"2026-03-04T05:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720\"},\"wordCount\":424,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0401.webp\",\"keywords\":[\"Asieris Pharmaceuticals\",\"Product approvals\",\"SHA: 688176\"],\"articleSection\":[\"Company\",\"Drug\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58720#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58720\",\"name\":\"Asieris Pharma's Cevira Wins NMPA Approval \u2013 World's First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0401.webp\",\"datePublished\":\"2026-03-04T05:03:00+00:00\",\"dateModified\":\"2026-03-04T05:03:01+00:00\",\"description\":\"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China's National Medical Products Administration (NMPA) for Cevira, a photodynamic drug\u2011device combination product. The world's first non\u2011surgical, non\u2011invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ\u2011preserving treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58720\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Asieris Pharma's Cevira Wins NMPA Approval \u2013 World's First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58720#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asieris Pharma&#8217;s Cevira Wins NMPA Approval \u2013 World&#8217;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Asieris Pharma's Cevira Wins NMPA Approval \u2013 World's First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China's National Medical Products Administration (NMPA) for Cevira, a photodynamic drug\u2011device combination product. The world's first non\u2011surgical, non\u2011invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ\u2011preserving treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58720","og_locale":"en_US","og_type":"article","og_title":"Asieris Pharma's Cevira Wins NMPA Approval \u2013 World's First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions","og_description":"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China's National Medical Products Administration (NMPA) for Cevira, a photodynamic drug\u2011device combination product. The world's first non\u2011surgical, non\u2011invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ\u2011preserving treatment.","og_url":"https:\/\/flcube.com\/?p=58720","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T05:03:00+00:00","article_modified_time":"2026-03-04T05:03:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58720#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58720"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Asieris Pharma&#8217;s Cevira Wins NMPA Approval \u2013 World&#8217;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions","datePublished":"2026-03-04T05:03:00+00:00","dateModified":"2026-03-04T05:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58720"},"wordCount":424,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58720#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp","keywords":["Asieris Pharmaceuticals","Product approvals","SHA: 688176"],"articleSection":["Company","Drug","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58720#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58720","url":"https:\/\/flcube.com\/?p=58720","name":"Asieris Pharma's Cevira Wins NMPA Approval \u2013 World's First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58720#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58720#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp","datePublished":"2026-03-04T05:03:00+00:00","dateModified":"2026-03-04T05:03:01+00:00","description":"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA:\u202f688176), a urogenital cancer specialist, announced marketing approval from China's National Medical Products Administration (NMPA) for Cevira, a photodynamic drug\u2011device combination product. The world's first non\u2011surgical, non\u2011invasive therapy for cervical intraepithelial neoplasia grade 2 (CIN2) represents a paradigm shift from surgical excision to topical, organ\u2011preserving treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58720#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58720"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58720#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp","width":1080,"height":608,"caption":"Asieris Pharma's Cevira Wins NMPA Approval \u2013 World's First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58720#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Asieris Pharma&#8217;s Cevira Wins NMPA Approval \u2013 World&#8217;s First Non\u2011Surgical Photodynamic Therapy for Cervical Lesions"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58720"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58720\/revisions"}],"predecessor-version":[{"id":58723,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58720\/revisions\/58723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58722"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}